Servier’s Voranigo Receives FDA Nod for IDH Inhibitor as Brain Tumor Treatment
The U.S. Food and Drug Administration (FDA) has granted first-time approval for Voranigo (vorasidenib), a...
Drug
Akeso Biopharma Initiates Phase III Clinical Trial for Cadonilimab in Hepatocellular Carcinoma
Akeso Biopharma (HKG: 9926), a biopharmaceutical company based in China, has announced the first patient...
Walvax Biotechnology’s HPV Vaccine Price Cut Sparks Potential Market Price War in China
Walvax Biotechnology Co., Ltd (SHE: 300142) has significantly reduced the price of its bivalent human...
Antengene’s Xpovio Receives NDA Approval in Malaysia for Multiple Myeloma Treatment
Antengene Corp., Ltd (HKG: 6996), a biopharmaceutical company based in China, has announced the approval...
Hotgen Biotech’s SGC001 Receives NMPA Approval for Clinical Trials in Myocardial Infarction
Hotgen Biotech Co., Ltd (SHA: 688068), a biopharmaceutical company based in China, has announced that...
Suzhou Zelgen Biopharmaceuticals’ ZG005 Receives NMPA Approval for Clinical Trials in Solid Tumors
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a biopharmaceutical company based in China, has announced...
Gan & Lee Pharmaceuticals Gets FDA Green Light for Phase I Clinical Trial of Insulin Aspart Biosimilar
Gan & Lee Pharmaceuticals (SHA: 603087), a leading pharmaceutical company based in China, has received...
Luye Pharma’s LY03020 Receives NMPA Approval for Schizophrenia and Alzheimer’s Psychosis Treatment
Luye Pharma Group (HKG: 2186), a China-based pharmaceutical company, has announced that it has received...
CMS’s Methotrexate Injection Gains NMPA Approval for Active Rheumatoid Arthritis Treatment
China Medical System Holdings (CMS; HKG: 0867) has received approval from the National Medical Products...
Takeda’s Vonicog Alfa Receives NMPA Approval for Von Willebrand Disease Treatment in China
Takeda Pharmaceutical Company Limited (TYO: 4502 / NYSE: TAK), a leading Japanese pharmaceutical company, has...
Shionogi Files for Chinese Approval of Cefiderocol to Combat Gram-Negative Bacterial Infections
Shionogi Co., Ltd, a prominent Japanese pharmaceutical company, has announced the filing of a New...
Degen Biopharmaceutical’s DG01 PROTAC Drug Receives NMPA Clearance for Solid Tumor Studies
Suzhou Degen Biopharmaceutical Co., Ltd, a leading specialist in PROteolysis TArgeting Chimeras (PROTAC) technology in...
Chongqing Genrix’s GR1803 Earns Breakthrough Therapy Designation in China for RRMM Treatment
The Center for Drug Evaluation (CDE) of China has indicated that Chongqing Genrix Biopharmaceutical Co.,...
Lepu Biotechnology’s MRG003 Earns FDA Breakthrough Therapy Designation for Nasopharyngeal Carcinoma
Lepu Biotechnology Co., Ltd (HKG: 2157), a biopharmaceutical company based in China, has announced that...
Yantai Dongcheng Pharmaceutical Secures NMPA Nod for PSMA-Targeted Radiotherapeutic Drug
Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a leading pharmaceutical company based in China,...
Innovent Biologics and Sanegene Bio Commence Phase I Clinical Trial for Hypertension siRNA Drug
Innovent Biologics Inc. (HKG: 1801), a leading biopharmaceutical company based in China, in collaboration with...
Walvax Biotechnology’s Bivalent HPV Vaccine Earns WHO Pre-Qualification Status
China-based Walvax Biotechnology Co., Ltd (SHE: 300142) has achieved a significant milestone with its bivalent...
Akeso Biopharma Initiates Phase II Global Study for Ligafulimab in High-Risk MDS
China-based Akeso Biopharma (HKG: 9926) has reached a clinical milestone with the dosing of the...
AbbVie Completes Acquisition of Cerevel Therapeutics in $8.7 Billion Deal
US pharmaceutical giant AbbVie Inc. (NYSE: ABBV) has announced the successful completion of its acquisition...
Lee’s Pharmaceutical Commences Phase I Clinical Trial for AI-Discovered HCC Drug AU409
Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), a leading biopharmaceutical company based in China, has announced...